Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Scisparc Ltd (SPRC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: SPRC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -83.4% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.93M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 4180421 | Beta 0.85 | 52 Weeks Range 0.20 - 2.10 | Updated Date 04/5/2025 |
52 Weeks Range 0.20 - 2.10 | Updated Date 04/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -419.88% |
Management Effectiveness
Return on Assets (TTM) -38.85% | Return on Equity (TTM) -85.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 433041 | Price to Sales(TTM) 1.68 |
Enterprise Value 433041 | Price to Sales(TTM) 1.68 | ||
Enterprise Value to Revenue 0.25 | Enterprise Value to EBITDA 1.21 | Shares Outstanding 10828300 | Shares Floating 3585745 |
Shares Outstanding 10828300 | Shares Floating 3585745 | ||
Percent Insiders - | Percent Institutions 1.21 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Scisparc Ltd
Company Overview
History and Background
SciSparc Ltd (SPRC) is a specialty pharmaceutical company focused on developing cannabinoid-based treatments. Formerly known as Therapix Biosciences, it was incorporated in 2004 and has evolved to focus on central nervous system (CNS) disorders.
Core Business Areas
- Cannabinoid-Based Pharmaceuticals: Develops and commercializes pharmaceutical products based on cannabinoids, primarily focusing on CNS disorders such as Tourette Syndrome and Alzheimer's Disease.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure is typical of a small pharmaceutical company with distinct departments for research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- SCI-110: SCI-110 is SciSparc's lead drug candidate. It is intended for the treatment of Tourette Syndrome. The competitive landscape includes existing treatments for Tourette's, such as antipsychotics, and other investigational drugs in development by competitors.
- SCI-210: SCI-210 is being developed for the treatment of Alzheimer's Disease. Competition includes established Alzheimer's drugs, and several companies developing novel treatments. SCI-210 targets the endocannabinoid system which is a novel target for Alzheimer's Disease.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in the CNS space, is highly competitive and regulated. There's increasing interest in cannabinoid-based therapies, creating both opportunities and challenges.
Positioning
SciSparc is a small player in a large industry. Its competitive advantage lies in its focus on cannabinoid-based treatments and its portfolio of clinical-stage assets.
Total Addressable Market (TAM)
The combined TAM for Tourette Syndrome and Alzheimer's disease is estimated to be in the tens of billions of dollars. SciSparc's positioning is based on its unique approach of using cannabinoids to treat these conditions, allowing it to carve out a niche within the larger market.
Upturn SWOT Analysis
Strengths
- Focus on cannabinoid-based therapies
- Pipeline of clinical-stage assets
- Experienced management team
Weaknesses
- Limited financial resources
- Small market capitalization
- Dependence on clinical trial success
Opportunities
- Potential for partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expanding market for cannabinoid-based therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
Competitors and Market Share
Key Competitors
- GWPH
- CGC
- CRBP
Competitive Landscape
SciSparc faces competition from established pharmaceutical companies and other firms developing cannabinoid-based therapies. Its success depends on differentiating its products and demonstrating clinical efficacy.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by progress in clinical trials and securing funding.
Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization of its drug candidates. Analyst estimates are subject to change.
Recent Initiatives: Recent initiatives include advancing clinical trials for SCI-110 and SCI-210 and exploring strategic partnerships.
Summary
SciSparc is a small, clinical-stage pharmaceutical company focused on cannabinoid-based therapies. Its success hinges on the results of its clinical trials and the ability to secure funding. The company faces significant competition from larger players but has the potential to capitalize on the growing interest in cannabinoid-based treatments. Investors should closely monitor clinical trial progress and financial health.
Similar Companies
CRBP
Corbus Pharmaceuticals Holding
CRBP
Corbus Pharmaceuticals Holding
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share numbers are rough estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scisparc Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-08-30 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://scisparc.com |
Full time employees 3 | Website https://scisparc.com | ||
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.